Muharrem Coşkunpınar (@mcpinar) 's Twitter Profile
Muharrem Coşkunpınar

@mcpinar

MD,
@AnkaraUni Medical Oncology Fellow 🦀🧬

ID: 1064127786

linkhttps://www.researchgate.net/profile/Muharrem-Coskunpinar?ev=hdr_xprf calendar_today05-01-2013 22:17:10

1,1K Tweet

223 Followers

220 Following

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

🔬 Klinik Araştırma Nedir? Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır. Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar, hem de gelecekte binlerce hayatın değişmesine

🔬 Klinik Araştırma Nedir?
Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır.

Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar,
hem de gelecekte binlerce hayatın değişmesine
Mustafa Özdoğan, MD (@ozdogan_md) 's Twitter Profile Photo

📢 #FDA approved another bladder-preserving treatment! The intravesical mitomycin gel offers a new option for patients with recurrent low-grade NMIBC. In the last 5 years, therapeutic alternatives have expanded meaningfully. A hopeful era for bladder preservation. 🌟 📊 See

📢 #FDA approved another bladder-preserving treatment!

The intravesical mitomycin gel offers a new option for patients with recurrent low-grade NMIBC.

In the last 5 years, therapeutic alternatives have expanded meaningfully. A hopeful era for bladder preservation. 🌟

📊 See
Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

🚨 Our new study alert! Elsevier What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No

🚨 Our new study alert! <a href="/ElsevierConnect/">Elsevier</a> 

What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma?

🎯Endpoints : Overall surival and time to treatment failure

High comorbidity 🟰 Worse Outcomes

❓❗️No
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Big news from nature 🔍 Transparent peer review is now standard for all research papers. Referee reports + author replies will be published with each article. More clarity. More trust. More accountability. How do you think this will affect science? #Science #PeerReview

Big news from <a href="/Nature/">nature</a> 
🔍 Transparent peer review is now standard for all research papers.
Referee reports + author replies will be published with each article.

More clarity. More trust. More accountability.
How do you think this will affect science?

#Science #PeerReview
The Nobel Prize (@nobelprize) 's Twitter Profile Photo

Do you play an instrument? In 1937, Albert Einstein met the Polish violinist Bronislaw Huberman. They talked about music and life at Einstein's home in Princeton, New Jersey. Einstein was very fond of music and started playing the violin from an early age. #WorldMusicDay

Do you play an instrument?

In 1937, Albert Einstein met the Polish violinist Bronislaw Huberman. They talked about music and life at Einstein's home in Princeton, New Jersey. Einstein was very fond of music and started playing the violin from an early age. 

#WorldMusicDay
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Honored to share our reflections on #ASCO25 GU highlights in The ASCO Post ASCO From kidney to bladder to prostate cancer key updates, simply explained. OncoAlert Jame Abraham, MD, FACP #ProstateCancer #BladderCancer #KidneyCancer #Cancer #Oncology #MedX

Beliz Bahar Karaoğlan (@bbahark) 's Twitter Profile Photo

⭐️Poster session at #ESMOGI has started!Come check out my poster 429P–Prognostic Significance of HER2-Low Status in Advanced Gastric Cancer. If you're interested in and potential collaboration,I'd be happy to connect! ESMO - Eur. Oncology Yüksel Ürün Deniz Can Guven Erman Akkus Ankara Üniversitesi

⭐️Poster session at #ESMOGI has started!Come check out my poster 429P–Prognostic Significance of HER2-Low Status in Advanced Gastric Cancer. If you're interested in and potential collaboration,I'd be happy to connect! <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/DrYukselUrun/">Yüksel Ürün</a> <a href="/DenizCanGuven1/">Deniz Can Guven</a>
<a href="/Erman_Akkus/">Erman Akkus</a> <a href="/AnkaraUni/">Ankara Üniversitesi</a>
Erman Akkus (@erman_akkus) 's Twitter Profile Photo

🟠Poster session in #ESMOGI25 📋A lot of great studies in the poster session ✅Thanks all authors and ESMO - Eur. Oncology for this rich content! #cancer #oncology #biliary #MedX Beliz Bahar Karaoğlan Deniz Can Guven

🟠Poster session in #ESMOGI25 

📋A lot of great studies in the poster session 
✅Thanks all authors and <a href="/myESMO/">ESMO - Eur. Oncology</a> for this rich content!

#cancer #oncology #biliary #MedX <a href="/BbaharK/">Beliz Bahar Karaoğlan</a> <a href="/DenizCanGuven1/">Deniz Can Guven</a>
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Sizce onkolojideki en büyük sorun ne? Sorduk. Cevaplar düşündürücüydü. Geç tanı ve doktora ulaşmak en çok belirtilen sorun. Tedaviye erişim ve maliyet onu takip ediyor. Yanlış bilgi ve yan etkiler de sıkça dile getirilen diğer problemler. Ama sadece bunlarla sınırlı değildi.

Sizce onkolojideki en büyük sorun ne?
Sorduk. Cevaplar düşündürücüydü.

Geç tanı ve doktora ulaşmak en çok belirtilen sorun.
Tedaviye erişim ve maliyet onu takip ediyor.
Yanlış bilgi ve yan etkiler de sıkça dile getirilen diğer problemler.

Ama sadece bunlarla sınırlı değildi.
Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

Happy to share our insights in this invited commentary published in "Kidney Cancer" Huge congrats our rising ⭐️⭐️⭐️ fellow Hatice Bölek from Ankara Üniversitesi ! ⁉️Immunotherapy re-challenge appears to have limited efficacy in kidney cancer. What might be the underlying reasons from

Happy to share our insights in this invited commentary published in "Kidney Cancer" Huge congrats our rising ⭐️⭐️⭐️ fellow <a href="/hatice_bolek/">Hatice Bölek</a> from <a href="/AnkaraUni/">Ankara Üniversitesi</a> !

⁉️Immunotherapy re-challenge appears to have limited efficacy in kidney cancer. What might be the underlying reasons from
Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

Huge congrats to our amazing fellow Muharrem Coşkunpınar ! His dedication, integrity, and humility are paving the way for him to become an exceptional physician-scientist. We are fortunate to have him in our department at Ankara Üniversitesi . Can't wait to see more from him! Yüksel Ürün

Muharrem Coşkunpınar (@mcpinar) 's Twitter Profile Photo

Thank you so much Prof. Yüksel Ürün . I sincerely appreciate your continued support and guidance since the beginning of my fellowship. My colleagues and I consider ourselves privileged to be under your mentorship.

Muharrem Coşkunpınar (@mcpinar) 's Twitter Profile Photo

Thank you for your encouraging words and for being a constant source of inspiration and role model. I feel lucky to work with you 🙏🙏 Emre Yekedüz

Regina Barragan-Carrillo (@reginabarcar) 's Twitter Profile Photo

🔥 What’s the hottest topic in oncology right now? CANCER + THE MICROBIOME. We reviewed the current evidence on how manipulating the gut microbiome can enhance immunotherapy, and what’s next. Led by @MontyPal with insights from Zeynep Zengin and me. 📍Read here:

🔥 What’s the hottest topic in oncology right now?
CANCER + THE MICROBIOME.

We reviewed the current evidence on how manipulating the gut microbiome can enhance immunotherapy, and what’s next.

Led by @MontyPal with insights from <a href="/ZeynepZengin/">Zeynep Zengin</a> and me.
📍Read here:
Mario Balsa (@mariobalsamd) 's Twitter Profile Photo

📄 In Cancer Cell: excercise reshapes gut microbiota, boosting ICI response in melanoma: cell.com/cell/abstract/… ▪️↑ Formate → CD8+ T cell activation via Nrf2 ▪️↑ Antitumor immunity, ↑ ICI efficacy 💡Formate = potential biomarker for ICI benefit Who knew immune gains could

CA: A Cancer Journal for Clinicians (@cacancerjournal) 's Twitter Profile Photo

Geriatric oncology has made great strides in improving outcomes for older adults with cancer. In a 2024 #OpenAccess review, @rochgerionc et al discuss the why, what, and how of geriatric assessment for clinicians. Revisit it here: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @oncoalert #GeriOnc

Geriatric oncology has made great strides in improving outcomes for older adults with cancer. In a 2024 #OpenAccess review, @rochgerionc et al discuss the why, what, and how of geriatric assessment for clinicians.

Revisit it here: acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@oncoalert #GeriOnc
İmdat Eroğlu (@imdat_eroglu) 's Twitter Profile Photo

Grateful to ASCO for the #VMP 2025-26 opportunity! Honored to be mentored by one of GU oncology’s senior leaders. Excited to learn from Andrea Necchi and grow through this journey.